Paraneoplastic Neurological Disorders, Volume 200 covers new, recent descriptions of autoantibodies against neuronal cell surface antigens (only partly associated with paraneoplastic disorders) and the introduction of new immuno-oncological drugs that can contribute to diseases that are pathogenetically indistinguishable from paraneoplastic syndromes. Besides investigating the pathogenetic mechanisms of these disorders, this book also explores what the introduction of new drugs used in immune checkpoint inhibitor cancer therapy are teaching us in terms of immunopathogenesis. Following sections present individual syndromes (phenotypical clinical manifestations) of the CNS, PNS, NMJ, and muscle.

Finally, the book investigates the role of antibody markers that differentiate by cytoplasmic, nuclear, and neuronal cell surface reactivities. Side effects of the new immuno-oncological drugs increasingly used in cancer therapy are also covered.

• Profiles paraneoplastic diseases by tumor type
• Identifies the pathogenetic mechanisms of PNS and provides epidemiological analysis
• Presents individual syndromes of the CNS, PNS, NMJ, and muscle
• Investigates the role of antibody markers
• Differentiates cytoplasmic, nuclear, and neuronal cell surface reactivities
• Discusses immune-oncological drugs causing diseases that are indistinguishable from PNS
• Reviews therapeutic strategies and clinical approach to PNS patients